Home / Transcripts / ALK-Abelló A/S (ALKB) · August 20, 2026

ALK-Abelló A/S (ALKB) Earnings Call Transcript

August 20, 2026

Nasdaq Copenhagen DK Health Care Pharmaceuticals earnings 57 min

Earnings Call Speaker Segments

Per Plotnikof executive
#1

Good day, everyone, and thank you for attending this presentation of ALK's Q2 and first-half-year results. We appreciate all of you being here. On slide number 2, we'll introduce the speakers and go through the agenda. I'm Per Plotnikof, Head of Investor Relations. Joining me today are CEO Peter Halling and CFO Claus Steensen Sølje. Peter and Claus will take us through the quarterly highlights, markets, product trends, and financials. Following a brief strategy update, we'll move to the full-year outlook, and as usual, the call will conclude with a Q&A session. To begin, I'll pass things over to Peter for the highlights on slide 3. Please go ahead, Peter.

Peter Halling executive
#2

Thanks, Per, and I appreciate everyone joining this call. ALK kept up robust sales momentum during Q2, posting double-digit sales growth in every region, primarily powered by tablets and anaphylaxis products. Revenue rose 18% in local currencies, reaching close to 1.8 billion DKK, while EBIT climbed 19%. The EBIT margin held steady at 25%, since gains in gross margin were counterbalanced by ongoing investment in product launches, commercial infrastructure, R&D, AI, and other areas. Tablet sales once again surpassed 1 billion DKK, rising 22%. The tablets carrying the new pediatric indications for ACARIZAX and ITULAZAX kept delivering strong performance and played a growing role in bringing new patients into key markets. We still view pediatric indications as a major growth engine for ALK over many years ahead. Plenty of opportunities remain in this space. In China, the local Phase 3 trial for ACARIZAX is quickly nearing completion, with results anticipated in Q4 this year. Should those results be positive, we believe a significant opportunity will open up in China, the world's largest house dust mite market. If approved, ACARIZAX could launch in 2028. On neffy, we achieved additional progress on market access and launches.

Peter Halling executive
#3

Our total anaphylaxis business in Germany has been making solid strides, and neffy is off to an encouraging start in Canada. I'll return to that in a moment, but first let me note that revenue from neffy during the quarter remained fairly modest and came mainly from Germany and the US. That mirrors how early the launches still are, and in particular the UK situation, where drawn-out formulary approvals and administrative hurdles keep holding back the complete rollout of neffy. The UK healthcare system's ongoing reform is slowing the pace of market access gains, yet even so, our confidence in the UK opportunity remains very strong. At the EAACI Congress in Istanbul in June, we shared detailed data from our successful Phase 2 peanut tablet trial. Over 7,000 healthcare professionals attended the congress, and the scientific community showed keen interest in what we've achieved. The feedback we received on the peanut trial results was highly encouraging, and we continue to expect Phase 3 development to begin before the end of '26, with planning moving along nicely, including talks with both the EMA in Europe and the FDA in the US. Given the momentum behind tablets, we are revising our revenue outlook upward.

Peter Halling executive
#4

This update also gives more visibility into pricing and rebates. Germany has passed new legislation that raises the mandatory rebate on prescription drugs from 7 to 15.5%, and that change takes effect from 1st of January '27. We don't anticipate any effect in '26, and we stay confident about the strong growth outlook both in Germany and globally for the years ahead. Germany is ALK's largest market, representing roughly 25% of global revenue in 2025. So we're working hard to mitigate the financial impact of next year's rebate increase. The new scheme didn't catch us by surprise, though the magnitude of the increase was a bit higher than what we had guided to previously. Rebate policies in Germany have shifted repeatedly over many years, and we had anticipated the increase sooner. As a result, ALK has been getting ready for a scenario of this kind and will roll out initiatives to offset the impact. Not all the details are settled yet, including possible exemptions from the rebate increase; it is, however, clear that healthcare providers cannot and should not gain twice from the rebates, and we will therefore look to carefully rebalance our current agreements and contracts with the healthcare providers.

Peter Halling executive
#5

That higher rebate won’t alter ALK’s long-term financial goals, and our target remains growth above 10% in the years to come. Both our business platform and our market positions are strong, and Germany is still a key growth market for ALK. We will keep executing our strategy and drive toward solid results in the years ahead. Earlier today, we announced that Jakob Glenting has been appointed as the new Head of R&D. Jakob came to ALK in 2007 and has done extensive work at the boundary between commercial and science. He has been a central architect in multiple strategic developments at ALK, among them the partnerships with Torii, Abbott, Jemincare, and ARS Pharma. He has been heavily engaged in the pediatric expansion and in strategy development. Hardly anyone understands our patients better than Jakob. With his R&D background and a PhD in vaccines and immunology, he is an ideal leader to steer our innovation efforts. Jakob and the team will pursue this under the Allergy+ strategy and build a strong bridge to ALK’s commercial operations, including our long-term targets. His task will be to balance growth in the core business with expansion into existing and new adjacent allergy areas via our own pipeline, partnerships, and business development and licensing.

Peter Halling executive
#6

At this point, I’ll pass things over to you, Claus, to cover the regional trends found on slide 4.

Claus Steensen Sølje executive
#7

Thanks a lot, Peter. Turning to sales: every region posted double-digit growth in Q2, with Europe still out in front. Revenue in Europe rose 19% in local currencies, with tablets and anaphylaxis products the main drivers. That momentum held steady — Q2 sales growth matched Q1 exactly. Tablet sales climbed 27%, largely on higher volumes tied to the strong influx of new patients during the '25-'26 initiation season. The new pediatric and adolescence indications for ACARIZAX and ITULAZAX are still big growth contributors, while GRAZAX added a more modest amount. Tablet sales rose strongly across most Central and Western European markets, Germany and France among them. Strong growth, albeit from a smaller base, also came through in Eastern European markets like Poland, Slovakia, and the Czech Republic, and in the UK, where ACARIZAX and ITULAZAX won dual reimbursement for adult use last year. I'd also mention that only a few days ago, ACARIZAX and ITULAZAX for pediatric use got a positive endorsement from NICE in the UK. On another positive note, Sweden's government has just launched a new national allergy strategy that calls for allergy care that is more preventive, more effective, and more equal across the country.

Claus Steensen Sølje executive
#8

We anticipate that once these new guidelines are rolled out regionally, they will help more patients receive treatment with AIT. In Europe, combined sales of SCIT and SLIT-drops rose 4%, with SCIT growth driven by both the venom and non-venom subsegments in Central Europe. SLIT-drops sales, which are mainly marketed in France, picked up some momentum in Q2 following a slow start to the year. European sales of anaphylaxis and other products were up 28%. For our anaphylaxis products on their own, growth reached 30%, and this also became a key driver behind the 20% market growth in Europe. Our Jext autoinjector kept benefiting from tender wins, strong commercial execution, and intermediate competition supply issues in certain markets. The overperformance by Jext more than offset the slow uptake of EURneffy in the UK, as Peter mentioned earlier. North America revenue grew 13% in local currencies, supported by continued double-digit growth in both the US and Canada. Canadian tablet sales remained an important gross contributor, reflecting a growing number of customer touchpoints and solid demand, particularly for the tree tablet, Itulatek, which again got a boost from the pediatric indication. Tablet sales in North America were up 17%, with double-digit growth in both Canada and the US.

Claus Steensen Sølje executive
#9

SCIT sales came in flat, whereas revenue from anaphylaxis and other products rose 22%. That gain was tied partly to cost compensation from ARS Pharma for the copromotion of neffy, along with sales of PRE-PEN, diagnostics, and other products. Revenue in international markets climbed 18%, reflecting higher product shipments to China and Japan. SCIT shipments to China were up versus last year, when the renewal of ALK's import license weighed on shipments. In-market sales growth slowed temporarily while we moved to our new partner Jemincare, but a new sales setup is now in place, and in-market sales should pick up in the second half-year. Tablet revenue returned to growth, rising 9% in international market. Japan posted double-digit growth from product shipments and royalties. Supply from our Japanese partner's new API manufacturing facility for the CEDARCURE tablet has reached the market, and in-market sales of both CEDARCURE and MITICURE accelerated in Q2. We remain confident that ALK's revenue from Japan will pick up further in the second half-year as planned. Now let's continue to slide 5 with the product lines. Global tablet sales grew 22% to just over 1 billion DKK.

Claus Steensen Sølje executive
#10

For the second quarter in a row, sales came in above 1 billion DKK, and the pediatric launch provided strong support. Growth in Europe was the strongest, at 27% for tablets, with North America next at 17% and international markets at 9%. SCIT and SLIT-drops together reached 515 million DKK, a rise of 7%, largely on the back of ramped-up SCIT shipments to China. Anaphylaxis and other products brought in 267 million DKK, 26% higher. Jext gave sales a lift, and neffy added a contribution that is growing yet still modest. Moving to slide 6, the half-year financials: revenue for the half rose 18% in local currencies to 3.6 billion Danish kroner, with double-digit growth in every sales region and product line. Gross profit was 2.4 billion DKK, a gross margin of 68% versus 66% a year earlier, reflecting greater sales volumes, production efficiencies, and a sales mix shift toward a larger share of higher-margin ALK-branded products. Capacity cost rose 22% in local currencies to 1.4 billion Danish kroner, as we invested substantially in current and future growth drivers such as product launches, commercial infrastructure, and R&D, particularly the peanut and ALK-014 programs. Sales and marketing cost was up 25%.

Claus Steensen Sølje executive
#11

6 percentage points of that rise came from the US neffy copromotion expense and the marketing fee paid to our Chinese partners. Last year, these items affected our figures only minimally. Operating profit rose 20% in local currencies, reaching more than 1 billion Danish kroner. The EBIT margin stayed at 28%, since gross margin gains were offset by a somewhat higher capacity cost to revenue ratio, which we had guided for. Net profit came in at 776 million Danish kroner, compared with 617 million DKK a year earlier. Free cash flow rose to 889 million Danish kroner, helped by stronger earnings and working capital changes, including the timing of payables and lower CapEx investments. Free cash flow beat expectations, which is also why we have raised the full-year assumption for free cash flow slightly. The net debt to EBITDA ratio was still negative at 0.6. Overall, another strong quarter and a solid financial position, with high growth and margin resilience despite extra funds and resources allocated to growth initiatives. Let's now move on to slide 7 for the execution of the Allergy+ strategy. Peter, over to you.

Peter Halling executive
#12

Thanks, Claus. Now I'd like to walk you through a few of the Allergy+ initiatives we have planned for the near term. To begin with respiratory allergy: the pediatric tablet rollout keeps delivering very strong results and is playing a growing part in tablet growth. As of the end of Q2, the house dust mite tablet had been launched in 22 markets, North America among them, and the tree pollen tablet in 13. Our key performance indicators remain robust. In the markets we serve directly, roughly 4,500 prescribers have now written at least one prescription for one of the two tablets in children. About 20% of those physicians had never prescribed any ALK tablets previously. That tells us we are broadening our prescriber base in existing markets. At present our priority is, above all, to deepen penetration and keep prescriber adoption going, though we are also continuing to pursue prescriber expansion. As I noted earlier, the local Phase 3 trial of ACARIZAX in China is set to finish in Q4, with a filing anticipated in '27 and possible approval in '28. In Japan, the GRAZAX Phase 3 trial is still progressing toward completion in '27, with a potential filing that same year. We expect further lifecycle management work over the coming years, designed to keep strengthening the value proposition of our core business.

Peter Halling executive
#13

On the anaphylaxis side in Europe, the rollout of neffy — that's EURneffy there — is still moving forward. Just a few days back, the 2-milligram strength became available in Canada, which is a key market, and that takes the count of countries where the product can be obtained to 10. The 1-milligram strength aimed at younger kids has been cleared throughout Europe, the UK included, and it is still awaiting approval in Canada as well as other markets. We're working through market access in a number of places, and we expect a lot of further launches in the coming six months, which lets us begin to build a larger neffy business over the years to come. As I said at the start, we've made solid headway on market access in Canada with the public payers and with commercial plans alike, and while it's still early, the first feedback from the launch is encouraging. Progress has also been good for our overall anaphylaxis business in Germany. Since the start of '25, our market share has doubled and now sits near 50%, with both Jext and EURneffy driving that. This came as the market grew roughly 20% in '26. Over that stretch we managed to increase EURneffy sales and hold a healthy market share, even through the recent peak season.

Peter Halling executive
#14

Tender wins have been a boost for Jext as well, and that's a really significant segment of the German market. Last, turning to food allergy and new disease areas: within only a few months, we intend to launch the pivotal Phase 3 study of the peanut tablet. Our preparations are quite far along. We've opened a positive, constructive conversation with the relevant authorities regarding the Phase 3 plans, and pending their final feedback, we anticipate going live by the end of the year, with patients enrolled from both sides of the Atlantic. Beyond that, under our wider food allergy portfolio strategy, we're likewise making encouraging headway with ALK-014, a biologic candidate that targets the key mediator of allergic reactions. Clinical development is expected to begin in '27. This program could be applied to food allergy along with numerous other IgE-mediated allergic diseases. Early next year, we also anticipate interim data from ARS's Phase 2b trial of neffy, which is evaluating rapid relief of acute flares tied to chronic spontaneous urticaria — a potentially very compelling add-on for ALK's product portfolio. Overall, the work of reinforcing existing revenue streams and creating new ones goes on. We're eager to share progress on these initiatives and others.

Peter Halling executive
#15

Now I'll return it to you, Claus, along with the full-year outlook that's on slide 8.

Claus Steensen Sølje executive
#16

Thanks, Peter. We've chosen to lift the bottom end of our revenue guidance range. Our expectation now is revenue growth of 14 to 16% in local currencies, compared with the earlier outlook of 13 to 16% growth. The EBIT margin remains projected at roughly 26%. This clarification mirrors the sustained strong momentum in tablet sales, especially in Europe, together with reduced risk around price and rebate adjustments, once it became evident that the German rebate increase won't take effect until next year. We anticipate volume-driven revenue growth across sales regions and product groups. Tablet sales should rise by double digit in every region, with children and adolescents forecast to make up a growing portion of the sales. Combined SCIT and SLIT-drop sales are expected to increase by single digits, whereas sales of anaphylaxis and other products should rise by low double digits. As always, shipment timing to China and Japan can lead to quarterly fluctuations. Gross margin is now anticipated to be slightly above last year's level, driven by positive volume and mix effects, though growth in lower-margin partner-related revenue will partly offset these. Capacity costs remain on track to rise as we keep reinvesting scale benefits into strategic initiatives.

Claus Steensen Sølje executive
#17

Being careful about where we put our capital and staying disciplined about priorities is still essential for us. Our expectation now is that free cash flow will strengthen even more and come in above 1 billion Danish kroner, helped in part by smarter CapEx spending. So to wrap up, momentum across the business is still robust. We look for us to carry on a path of double-digit organic revenue growth, which would mark the eighth year in a row, with an EBIT margin a little higher than our long-term financial ambitions. That said, I'll turn things back over to you, Per, and to slide 9.

Per Plotnikof executive
#18

Thanks, Claus, and thanks, Peter. That brings our presentation to a close, and now we'll begin the Q&A portion. Operator, please go ahead.

Operator operator
#19

That brings us to the Q&A portion of today's call. Should you wish to pose a question, on a touchtone phone press star followed by one. If you need to pull your question, press star and then two. For those on a speakerphone, we kindly ask that you lift the handset before hitting the keys so the sound quality stays as good as possible. Once more, that's star then one to get into the question queue. Our first questioner this afternoon is Ben Jackson of Jefferies. Please go ahead with your question.

Benjamin Jackson analyst
#20

Great, thanks for the question. So first, could we spend a bit more time on your early thinking regarding 2027? I think the main thing here is the somewhat cryptic commentary you're providing about possibly mitigating those German rebates in 2027. I suppose that's partly about things like flexibility in contracting, inflation adjustments, and maybe even how you design clinical trials. Any thoughts or further detail on that mitigation, and then perhaps more broadly how we should think about the top-line build into next year? It's early, but it's useful for us. Then second, if I could just ask for a bit more color on the dynamics around neffy, please. In particular, a little commentary on how Canada has gone initially, where you stand on market share in Germany now versus when we last caught up, and then the outlook on when we should see the UK becoming a bit more meaningful here given the headwinds that are currently slowing down the initial launch. Thanks so much.

Peter Halling executive
#21

Thanks, Ben. Appreciated. I'll kick things off, and then Claus and Per can come in and add to it. First, on '27, since we aren't giving specific guidance for any particular year, but I will share some high-level thinking about where we're headed and, in particular, how we view the German market. Overall, we still see Germany as a key growth driver for ALK going forward. It has contributed strongly to our double-digit growth over the past years, and we expect that to keep going forward. As you also know, we've been discussing the German rebate and the expectation that it would rise in the past years, and all along we have been planning for how to tackle it. Obviously, a commission is now being put in place in Germany, and they have been tasked with the fact that the 15.5% rebate, what would potentially be allowed for exemptions to that rebate. We are attacking it from a couple of fronts. One is, if we look at the rebate as it is constructed and potentially with the exemptions, it may be that we can actually use the number of clinical trials with German patients to lower the rebate.

Peter Halling executive
#22

Right now, we don’t yet know if that will be part of it, though the committee is discussing it. Also, the talks about manufacturing in Germany, R&D in Germany, and so on have been less clear. What this indicates is that going forward there will be levers that could let a company such as ALK reduce the rebate amount we pay. The other side of the rebate is that, in essence, under how the German system operates, we pay a rebate straight to the German health authorities. As part of that process, they pass it straight to the insurers. We also have direct contracts with the insurers from the other direction, where we are negotiating a certain level of rebates as well. Now, what we expect is that this kind of paying a rebate twice from two directions is clearly something we will examine and something we believe can be negotiated with the German insurers, and that can also help us mitigate the rebate. Third, internally, we have known for some time that the rebate would arrive one day, and now it is in ’27. Above all, it gives us greater clarity.

Peter Halling executive
#23

We understand exactly where we are, and we also understand how to tackle it. So that means we've been examining which initiatives we might keep going with or might not, and in what shape, and that lets us make clear decisions fast and put them into action. And then lastly, I'd say, keep in mind that ALK has been expanding faster than our long-term targets. That has let us invest ahead of the curve as well, and it means we've managed to make commercial investments more swiftly than we did or could do on the basis of our earlier projections. That also lets us put money into markets such as Germany, and we've been doing so for some time, and that gives us a solid foundation as we move forward too. For example, the TAU, essentially the shift from unregistered products to registered products, wraps up toward the close of this year, which means prescribers and patients will have to move from unregistered to registered products. That hands ALK a big opportunity through our portfolio to grab part of that business as we go forward. That also opens up chances for us that we didn't have before when we look toward '27. It's simply to give you a sense of how we actually plan to soften some of this, and how we view the German market as we go forward.

Peter Halling executive
#24

One final point on Germany: we regard it as a core European market. In our view, this market holds substantial growth potential in the periods ahead. The rebate is a one-time occurrence. It could be altered down the road in either direction, but Germany continues to be, as it always has been, a key country within ALK's portfolio. I hope that provides a bit of color on that topic, Ben. Turning to neffy, you asked whether we might elaborate somewhat on Canada, Germany, and the UK. I'm happy to begin, and then I think you all can simply chime in. Canada is still early days, in my view, though what gives us encouragement is that certain market access hurdles you might potentially encounter in a market such as Canada — which is somewhat comparable to the US — have not materialized for us. We've managed to mitigate a portion of that through patient programs, and that likewise means the flow is smoother. From the patient's perspective, when you obtain a neffy, you don't run into some of those same market access problems seen in the US involving rejections; we have a clear flow-through.

Peter Halling executive
#25

That’s been encouraging, and we’ve observed the same effect as wholesalers pull product through into pharmacies. All in all, a solid beginning—though keep in mind we’re only about 3 or 4 weeks into the launch, but still a solid beginning. Germany, I’d say, is a very clear illustration of a market with fewer market access restrictions. It’s a market where, once neffy can flow freely in, we’ve observed a fairly robust adoption rate. So why are we slowing somewhat? There are two reasons. First, a portion of the German market is a tender market, and there we’ve been very glad to see that our emphasis on neffy and on the anaphylaxis portfolio, Jext included, has allowed us to win tenders in Germany as well, which has given us a stronger portfolio and a stronger overall business. Second, in Germany you’d normally also see peak seasons typically during parts of the summer. That’s where we were keen to see whether neffy would hold its market share, and it has been holding its market share. That’s typically when you see a lot of the auto-renewals.

Peter Halling executive
#26

Germany has likewise seen a favorable effect from that. At the same time, we remain realistic about the German market. General practitioners still account for a substantial share of that market and they prescribe autoinjectors, so guidelines must be put in place there. In other words, the guidelines need updating so that neffy, or a nasal device, stands on equal footing with autoinjectors, including from a guidelines perspective, and that takes time. Naturally, this leads us to the UK. Regarding the UK market, we have to acknowledge that we did not foresee how complex a healthcare system undergoing reform would be. As Claus mentioned on the call, and as we said earlier today as well, we stay very optimistic about that market. There is no question the product has been very well received in the UK: patients, the patient organization, doctors, and even authorities view it positively. Our challenge now is not just securing formulary access but also ensuring budgets are in place and then getting onto the lists at local hospitals. That has taken longer than we expected, and it has been made more complicated by the shift from 42 regions to 26 regions in the UK, along with downsizing and cost budget reforms on top of that.

Peter Halling executive
#27

That has slowed things down, but it doesn’t change the fact that the UK is still among the largest markets for anaphylaxis products, and we think neffy has a very strong position there going forward. It’s just a question of time. Claus, Per, anything to add? Ben, I hope that gave you some insight.

Benjamin Jackson analyst
#28

That’s quite helpful. Thanks.

Operator operator
#29

Thomas Bowers from SEB has our next question. Go ahead, please.

Thomas Bowers analyst
#30

Thank you very much. I have a few questions for you. Perhaps I'll start with the peanut project. You referred to constructive discussions with regulators. Should I take that to mean conversations with both the FDA and EMA? Do you already have any preliminary conclusions regarding the TV versus ED endpoint at this stage? And what remaining gating factors are there before the study can begin in the fourth quarter? My second question concerns the full-year guidance. Given the very strong Q2 figure, reaching the midpoint of your revised growth guidance implies 13% for H2. What is actually stopping you from lifting the top end of guidance today? Is it mainly uncertainty around the initiation season, or mostly the timing of shipments to international markets? And finally, on pediatrics. Could you give us more detail on where things stand with the pediatric rollout for ACARIZAX and ITULAZAX? I know it's probably still early, but where are we percentage-wise in terms of total prescriptions? I recall GRAZAX being at roughly 30 to 40% of prescriptions in Europe or Germany.

Thomas Bowers analyst
#31

Are we getting sort of near that figure, or does it remain a long way off? Thanks.

Peter Halling executive
#32

Thanks, Thomas. Let me get us started briefly. I'll pass things to Per, and on the full-year guidance, Claus, perhaps you could weigh in on the peds as well, and we can chime in where needed. Regarding the peanut Phase 3, yes, we've held meetings with both the FDA and EMA. I'd say our dialogue with both has been very constructive. What pleases us greatly is that they've confirmed they share our view that we have solid Phase 2 data. We feel confident about proceeding into Phase 3. We still have to submit and receive final approval for the trial designs before we can begin, but we stay optimistic about entering Phase 3 toward the end of the year. Overall, good dialogue, though we need to finalize it. Per, would you like to add a bit more on the peanut?

Per Plotnikof executive
#33

Okay. On the precise trial design, it's still too soon to draw conclusions, since we're continuing to negotiate those specifics. After the authorities approve the trial protocol, we'll communicate with the market, and that's anticipated to take place later this year. We'll then start the study, also later this year. Having detailed discussions about the trial design before the authorities have approved it is a bit too premature. That's the status on that one. Claus? Full-year guidance?

Claus Steensen Sølje executive
#34

Yeah. Thanks, guys. On the full-year guidance — thanks, Thomas, for raising that question. You're correct that the first half was strong, with 18% growth. Naturally, we're now looking at a half-year in which, mathematically, we expect growth of somewhere between 11 to 15% in local currencies during the second half. I think it's worth pointing out that we still anticipate very strong momentum in the underlying business carrying on, so that's essentially not what's happening, and nothing we're seeing relates to the underlying business here. I think three items deserve attention. Please keep in mind that we face some tough comparisons against the second half of last year, when our revenue rose by 18%, particularly tablets and Jext in Europe. That's the comparison we're up against. Then, as you yourself noted, you're right that our key swing factors for the second half are always the timing of shipments to international markets, Japan and China, and those could be a swing factor, and we'd prefer to get a little further into the second year before we start to conclude on that. Then thirdly, there's our initiation season.

Claus Steensen Sølje executive
#35

We're actually coming off two solid initiation seasons, in both '24 and '25, and those are also driving our growth this year — which is, of course, a good thing, and it will keep doing so. We're anticipating some nice initiation seasons. At this point we can only go by the early signals from the spring, and those look good, but we also need to stay a bit cautious here, and we think it's prudent to hold off until we see how this initiation season gets underway, 1 1, 2 months from now. Once we know more about that, then we will, of course, report it out as soon as we can see something, but for now we believe the right thing is simply to wait a few more months to see where the second half is heading. I hope that gives you some flavor on that.

Peter Halling executive
#36

Claus, do you want to add something about the pediatric business as well?

Claus Steensen Sølje executive
#37

Sure, we can do that with pediatrics. What we're seeing leaves us quite pleased. In fact, we've been saying this for several quarters now. At present, we're in 22 markets for ACARIZAX and 13 markets for ITULAZAX. Children, we're finding, account for a progressively bigger portion of our growth share. Looking at it through the lens of new patients, we can see that close to 30% of new patients are children. We've mentioned before that at some stage we'd like to reach 50%, and we're getting there nicely and just as expected. It's a very encouraging development, and all we can add is that positive trends keep showing up on that front, in line with expectations and very favorable, so that's good.

Thomas Bowers analyst
#38

Hope and Thomas, I believe that covers it. Yes.

Operator operator
#39

The next question is from Jesper Ingildsen at DNB Carnegie. Go ahead, Jesper.

Jesper Ingildsen analyst
#40

Thanks. Three questions from me. To start with gross margin: you posted another robust gross margin in Q2. Could you help us grasp the cadence for the back half? You're now steering toward a gross margin modestly above last year's, yet if we factor in the usual kind of seasonality, what's the rationale for needing improvement over Q2? How does that square with the full-year outlook? I realize there's presumably a somewhat larger partner segment in the second half, but is there anything further that would help us better grasp that dynamic? Next, on tablet sales in international markets, you recorded quite strong growth in Q2, once again aided by the always-new manufacturing facilities coming online. Please help us understand what growth expectations look like for the second half. You're hinting at some of the equipment you typically have, but this appears very strong in Q2. Could we get any color on underlying demand in Japan, and what the efforts of Shionogi might potentially do to drive that acceleration once they at last receive confirmation for the takeover of Torii? And then perhaps lastly, on capital allocation, is there anything new you can share there?

Jesper Ingildsen analyst
#41

How are you thinking about BD at the moment? Should we still expect smaller bolt-ons, or is there something specific in the market that has your attention right now? And what would prompt you to begin returning some of that excess capital to investors? Thanks.

Peter Halling executive
#42

Thanks, Jesper. I’ll have Claus start us off on gross margin. I can cover the international tablets. We can talk jointly around the capital allocation. Claus will talk mainly on the CapEx, I’ll talk about the BD. Claus?

Claus Steensen Sølje executive
#43

Thanks, Jesper, for that question. You're correct that our gross margin is actually running higher than we had anticipated at this stage. Keep in mind that when we issued guidance last year, we had in fact projected larger shipments into both China and Japan, along with greater partner sales overall across the year. Because of that, we told you to anticipate a decline of 1 to 2 percentage points in gross margin for this year. Well, we've now revised that guidance. At present we're expecting a slight increase versus last year, and that's largely driven by the excellent work our manufacturing colleagues are doing. We're seeing good scrap levels. We're tracking the efficiencies at the manufacturing sites, but also by the fact that shipments into China and Japan are now delayed, which will have an effect. On the in-market side, I think it's worth noting, things are actually continuing to go very well in both China and Japan. Peter will also address in-market sales in Japan. From a gross margin standpoint, it's the shipments that are pushing things somewhat into the second half of the year, and that's why we're also saying that at this point, we expect more visibility on gross margin in the second half, and we'll finish around, yeah, slightly better than last year.

Claus Steensen Sølje executive
#44

Looking ahead to the back half of the year, we're also observing stronger tablet sales across Europe, and that should lift the gross margin in that region as well. For the full year, we ought to land somewhat better than last year's result, and that's clearly a fairly meaningful upgrade relative to the guidance we gave for the full year 6 months ago.

Peter Halling executive
#45

Regarding tablets in international markets, Jesper, and Japan specifically, we keep observing genuinely robust underlying demand there. In-market sales remain solid, for MITICURE as well as CEDARCURE. Particularly with more API now becoming available, the task is satisfying that demand. We anticipate this will keep going, and in that context it's crucial that the whole supply chain is lined up so shipments go out on time and, to a big degree, as we have managed previously, so that demand gets met. Our view of Japan and its in-market growth is positive. Second, concerning the partnership with Torii and, shortly, Shionogi, it's worth noting that Shionogi has not yet completely vested the MA — the marketing authorization — that they hold at present, which also means a split exists between the Torii business and Shionogi. We are in talks with Shionogi, though those talks with Shionogi happen outside of the business we share with Torii. Naturally, that is always somewhat more of a difficult situation to be in, yet it's a natural situation when you witness some of these takeovers. We are holding off until we have full flow before communicating and discussing the Japanese market in particular.

Peter Halling executive
#46

Even so, that doesn’t stop us from talking about what this partnership can accomplish and how we might collaborate moving forward. I’ll say that we’re genuinely enthusiastic about the partnership with Torii as well as, certainly, the opportunity in front of us with Shionogi. Shionogi is an interesting partner. I think I’ll stop there, and perhaps, Claus, if you cover capital allocation broadly, I can address the BD side.

Claus Steensen Sølje executive
#47

Okay, I'll take that. Jesper, you're correct that we're naturally seeing certain opportunities, since the free cash flow you've been observing is going up. We've already made it clear that discipline will guide how we allocate capital; we're confident we'll keep enough flexibility to meet our growth ambition while also producing attractive returns for shareholders. Today's report also shows that our free cash flow is rising. Our guidance is even slightly above what we gave last quarter, so that too is heading in the right direction. Capital will keep being allocated in the order we outlined before. First comes investment in organic growth, R&D included. Second comes business development and licensing activities — Peter can speak to that. Third comes returning cash to shareholders through dividends and/or share buyback programs. That is, of course, also why we restarted dividend payouts earlier this year, and without question we'll keep focusing on that as well. This is the disciplined capital allocation we follow. The second of those was BD activities, Peter, which we're examining.

Peter Halling executive
#48

Yeah. There isn't anything particular we can comment on. I've mentioned this previously, but I also think you have to view it in the context that we believe there's more we can do on the BD side, though we want to pursue it for the right opportunities. As Claus said, we'll do it with a disciplined approach, but also with regard to our long-term financial targets, including EBIT, and including what we said about how we're going to allocate to the R&D function. We keep monitoring the market. We keep looking for opportunities globally, but especially we'd like to find something that could also be relevant for the US market. We keep working on that angle, and I'll promise you, if and when we find something, then we will make sure to communicate it based on what we can do there. I think that's as close as we get to that one. I hope that gave you some insights, Jesper.

Jesper Ingildsen analyst
#49

At this point, are we still mainly discussing bolt-on BD as opposed to something transformational, or how are you viewing that right now?

Peter Halling executive
#50

It really comes down to what you mean by transformational, but in no way are we considering fundamentally changing this company.

Jesper Ingildsen analyst
#51

Got it.

Operator operator
#52

Peter Røgkær with Nordea has our next question. Please proceed with what you'd like to ask.

Peter Hugreffe analyst
#53

Hello, Peter and Claus. Thanks very much for fielding my questions. Claus, apologies, I'd like to return to the implicit second half, since you were kind enough to address Thomas's questions on the top line, but I suppose an implied 3 to 8% EBIT growth might need some explaining — what gets you to 3%, because at present I honestly can't see it, so could you walk us through some of the building blocks there? Then a quick follow-up on capital allocation. Can I just ask when enough is enough when it comes to stockpiling cash? Right now it's 1.7. I'm curious to know when you risk going too far with dividend payments? And lastly, the hiring of Jakob Glenting — congratulations on that. Beyond what you said about the strategy, are you moving back toward a bit more of an ALK classic approach, or what should we expect from this new setup? Thank you very much.

Peter Halling executive
#54

Thanks, Peter. On the second half and the margin growth, I’ll have Claus respond. On capital allocation again, we can break it into parts. When is enough enough? I like how that’s phrased. Then, clearly, I’ll speak with Jakob too. Claus, would you like to start?

Claus Steensen Sølje executive
#55

Sure, I can address the full year, and Peter, thank you for those questions. You're obviously correct that earlier I only covered the top line. When you turn to the bottom line and EBIT, we're still seeing that really strong growth, 20% for the half-year. As we've said, guidance remains at roughly 26%. So how does that work? What are the building blocks behind the sales performing well and gross margin also improving? A few points deserve attention here. We keep putting money into both the children launches and, in particular, the neffy launches. Both represent major long-term opportunities for the company, and we'll make certain that investment in them continues. That also means that if we identify, so to speak, pockets of money where we can see the chance to invest even more to lock in organic growth across many years ahead, we'd want to pursue that. When such opportunities arise — say, additional investment openings and funds — we'd like to act on them. Then on the R&D side as well, we have of course the peanut, as we discussed just before.

Claus Steensen Sølje executive
#56

We’re doing everything possible to make this move faster. The conversations with FDA and EMA have been positive, which also gives us confidence that putting as much as we can into the peanut trial as quickly as we can is the right thing to do. Obviously, we shouldn’t go at it with our head under our arms, but when we can see that it makes sense, we do it. On top of that, we’re also beginning to invest in ALK-014, our own anti-IgE. We have some big bets—two commercial, two R&D—where we have an opportunity in the second half of this year to raise the investments, and these are the building blocks to keep the 26% EBIT margin. Should I also add, just at a high level, on when is enough enough? That’s a good one. I think we will steal that one. Of course, there’s no right or wrong answer there, but we are, of course, also debating internally when is enough enough. As Peter alluded to earlier—and maybe he can add a little bit more again on the BD—but of course we’d like to make sure that we also have opportunities financially so that if there is anything we find, then we can actually react on it quite fast.

Claus Steensen Sølje executive
#57

So at this point, we'd prefer to preserve that optionality. It also means if nothing turns up, then, as we've mentioned previously, being a bank isn't something we want. In that case we'll carry on with dividends — that's the plan — and a share buyback might present an opportunity. At present no plans exist, and naturally we'd let you know about it, but it could be an option should we determine that no BD opportunities are out there worth putting our cash into. We'll revisit this once we have something concrete.

Peter Halling executive
#58

Thanks, Claus. So on the BD side, and also with Jakob as our new Head of R&D — on BD, we'll keep exploring where the opportunities are. It's important for us to point out that when you look at how we laid out Allergy+, we know we've got a really solid foundation in the respiratory area. We also hold a high market share there, and that does constrain some of the moves you might imagine in that space. Looking at some of the other areas — the first being anaphylaxis — it was clear there was something we could do on BD. We did it, and I think bringing in neffy at a very low price was a really good deal, one that paid off more or less right away, and now the question is whether we can get it executed, which we believe we can. Then there's food, and there are also potentially new areas — the CSU example with neffy. In food, and also to supplement some of the other spaces, there may be options out there that could serve as examples and help us. We'd like to reinforce this, because the thinking and the strategy is a global play, the chance to become a strong number one or number two, with the ambition of always being number one, and then with a portfolio that means more than one product.

Peter Halling executive
#59

Take food, for example—right now we have peanut, and there's a case where we ask whether to handle something in-house or bring it in from outside. It comes down to price, opportunities, and timing. That's another reason we need to work through some of these matters. Incidentally, this will be a continuing internal discussion, and ideally we can satisfy investors' needs on every front. Then, on Jakob—first of all, I'm very pleased as well, and thank you for mentioning it, that we've found Jakob. Jakob went through a thorough process against outside candidates, and he emerged as the winner. As I said, that's because Jakob brings the right kind of expertise—25 years in the field plus a PhD and R&D background, a strong combination alongside an understanding of ALK, what we do, and what we need going forward. You asked whether this was a bit of a return to basics. I don't believe ALK ever left the basics, but we see it as an opportunity with Jakob to reinforce the partnership side, and also to truly build a stronger bridge between R&D and commercial, and to keep strengthening our position in the respiratory space as well as in some of these new spaces.

Peter Halling executive
#60

Jakob is bringing that expertise. And then keep in mind that Jakob has a team of nearly 400 people who are all specialists and subject-matter experts, and they've been essential to what we've achieved up to now. Fortunately, I think every one of them is staying with ALK in addition. I genuinely believe we have a solid base, but Jakob adds something more. I think he offers that blend that will let ALK scale and keep building and become and remain the number one leader in this space. Very happy, and hopefully you'll see it before long too, Peter. I hope that more or less covers the questions.

Peter Hugreffe analyst
#61

Thanks a lot. I appreciate it, everyone.

Operator operator
#62

Sushila Hernandez from Van Lanschot Kempen has our next question. Go ahead, please.

Sushila Hernandez analyst
#63

Yes, thanks for taking my question. Regarding neffy, what might the CSU opportunity represent for ALK, and if you chose to opt in following the Phase 2b data, what sort of investments would we be looking at? Thank you.

Peter Halling executive
#64

Thanks, Sushila. Regarding neffy CSU, from what I understand, it's neffy, and the Phase 2b trial is being run by ARS at the moment. We're now expecting the readout in Q1. The reason it's slipped a bit is essentially that when you conduct the trial, unfortunately you need to observe at least three incidents in a patient. As luck would have it, we can't control when that occurs for each patient, so we simply have to be patient and wait for it. That work is ongoing right now. Incidentally, a portion of it is taking place in Germany. We're clearly enthusiastic about the trial and about what the results could show. Now, as for the investments that come out of it, it's too early to say, but obviously, together with ARS, we'll look at the outcome and also the research we've completed and determine how to scale this. Essentially, as things stand, this is an ARS investment, with us holding the commercial rights outside of the US, though we are closely involved. If it pans out and if the business case proves as promising as what we've seen so far, then obviously we'll work hard to make sure we have the funds to commercialize the product as fast as possible.

Peter Halling executive
#65

That also hinges on what the European authorities, along with regulators in Canada, the UK, and other markets, end up asking for. We still have to wait and see on that front. Above all, we're awaiting the trial results, though we share ARS's enthusiasm regarding the potential. That said, I'd remind you that the amount paid in the US differs from what's paid outside the US. My view is that the potential outside the US can't realistically match one-to-one what you're seeing in the US; even so, it's a very exciting product with real promise for the future. Did that cover it, Sushila?

Sushila Hernandez analyst
#66

Understood. Thanks. Yes, got it. Thanks.

Operator operator
#67

Since there are no further questions, I'll hand the floor back to management for closing remarks.

Per Plotnikof executive
#68

Thanks so much, and I appreciate all the solid questions. Before we wrap up the call, I'd like to point out a handful of investor events and roadshows coming up over our three continents. We really hope you'll be able to join us at one of them. Also, please keep in mind that our Q3 report will come out on the 17th of November. The earlier plan had it scheduled for the 18th of November. That brings today's session to a close, and we wish everyone a pleasant day. Goodbye. Thank you.

Operator operator
#69

Thank you, everyone — that brings us to the end of today's conference call.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete ALK-Abelló A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to ALK-Abelló A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.